Zogenix is committed to developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with orphan diseases and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
Type
Public
HQ
Emeryville, US
Founded
2006
Size (employees)
67 (est)
Zogenix was founded in 2006 and is headquartered in Emeryville, US
Report incorrect company information

Zogenix Office Locations

Zogenix has an office in Emeryville, San Diego and Maidenhead
Emeryville, US (HQ)
455 5858 Horton St
San Diego, US
650 12400 High Bluff Dr
Maidenhead, GB
Broadway
Show all (3)
Report incorrect company information

Zogenix Financials and Metrics

Zogenix Financials

Zogenix's revenue was reported to be $28.85 m in FY, 2016 which is a 6.1% increase from the previous period.
USD

Revenue (Q2, 2017)

7.1 m

Net income (Q2, 2017)

(23 m)

EBIT (Q2, 2017)

(22.1 m)

Market capitalization (5-Feb-2018)

1 b

Cash (4-Feb-2018)

65.8 m

EV

986.6 m
Zogenix's current market capitalization is $1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

33 m40.5 m27.2 m28.9 m

Revenue growth, %

23%(33%)6%

Cost of goods sold

21.2 m15.8 m

Gross profit

11.8 m24.7 m27.2 m28.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

7.2 m7.7 m9.2 m8.8 m4.6 m7.4 m9.1 m9.2 m2.1 m6.6 m7.1 m

Cost of goods sold

5.4 m3.4 m2.4 m706 k

Gross profit

1.8 m4.3 m6.8 m8.1 m

Gross profit Margin, %

25%56%74%92%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

72 m42.2 m155.3 m91.6 m

Accounts Receivable

1.4 m1.4 m

Inventories

4.3 m13.4 m12 m12 m

Current Assets

92.9 m78 m184.6 m119.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

17.4 m50.7 m81.2 m50.5 m21.3 m77.4 m162.7 m132.2 m127.8 m109.9 m80.1 m65.8 m

Accounts Receivable

6.2 m11.7 m5.9 m5.9 m1.6 m6 m3.9 m4.9 m2.1 m6.5 m

Inventories

12.1 m14.9 m15.7 m19.3 m13.1 m12.6 m10.3 m9.5 m11.9 m9.4 m9.1 m2.2 m

Current Assets

37.4 m81 m116.5 m90.6 m55.2 m125.3 m200.6 m163.1 m149.5 m135.3 m98.8 m78.8 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(80.9 m)8.6 m26.1 m(69.7 m)

Depreciation and Amortization

1.8 m1.6 m1.6 m1.4 m

Inventories

(2 m)(9.2 m)(743 k)(743 k)

Accounts Payable

6.1 m5.6 m(14.2 m)(14.2 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Net Income

(45.2 m)49.6 m35 m(10.4 m)(29.2 m)(46.2 m)

Depreciation and Amortization

1.4 m406 k820 k1.2 m393 k814 k1.2 m378 k694 k966 k

Inventories

542 k3 m2.6 m186 k2.6 m

Accounts Payable

205 k6.9 m10.7 m2.4 m947 k(9.9 m)(11.6 m)(4.3 m)(3.9 m)(4.3 m)
USDY, 2017

EV/EBIT

-44.7 x

Financial Leverage

2.4 x
Show all financial metrics
Report incorrect company information